14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $146M | -$196M | 0.0% | -62.1% | -$75M | — | $61M |
| 2024 | $145M | -$76M | 0.0% | -82.2% | -$128M | — | $62M |
| 2023 | $146M | -$143M | 0.0% | -88.7% | -$93M | — | $52M |
| 2022 | $157M | -$165M | 0.0% | -90.5% | -$150M | — | $135M |
| 2021 | $210M | -$124M | 0.0% | -46.8% | -$107M | $169M | $190M |
| 2020 | $108M | -$196M | 0.0% | -159.0% | -$160M | — | $86M |
| 2019 | $41M | -$200M | 0.0% | -462.9% | -$191M | — | $129M |
| 2018 | $30M | -$178M | 0.0% | -593.0% | -$161M | — | $118M |
| 2017 | $2M | -$129M | 0.0% | -8133.2% | -$74M | — | $69M |
| 2016 | $154000 | -$110M | 0.0% | -71903.9% | -$84M | — | $50M |
| 2015 | — | -$118M | — | — | — | — | $58M |
| 2014 | — | -$76M | — | — | — | — | $151M |
| 2013 | — | -$34M | — | — | — | — | $156M |
| 2012 | — | -$16M | — | — | — | — | $391000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $35M | -$22M | 0.0% | -76.3% | — | — | $91M |
| Dec '25 | $34M | -$102M | 0.0% | -52.4% | -$12M | — | $61M |
| Sep '25 | $44M | -$33M | 0.0% | -34.6% | -$6M | — | $38M |
| Jun '25 | $38M | -$37M | 0.0% | -64.3% | -$19M | — | $39M |
| Mar '25 | $30M | -$23M | 0.0% | -110.8% | -$39M | — | $39M |
| Dec '24 | $31M | -$31M | 0.0% | -102.4% | -$26M | — | $62M |
| Sep '24 | $39M | -$32M | 0.0% | -67.8% | -$19M | — | $73M |
| Jun '24 | $43M | $24M | 0.0% | -65.7% | -$38M | — | $85M |
| Mar '24 | $33M | -$37M | 0.0% | -101.9% | -$44M | — | $31M |
| Dec '23 | $34M | -$42M | 0.0% | -112.0% | -$19M | — | $52M |
| Sep '23 | $36M | -$35M | 0.0% | -86.8% | -$30M | — | $44M |
| Jun '23 | $38M | -$33M | 0.0% | -78.7% | -$26M | — | $81M |
| Mar '23 | $39M | -$34M | 0.0% | -79.8% | -$19M | — | $84M |
| Dec '22 | $34M | -$39M | 0.0% | -100.9% | -$27M | — | $135M |
| Sep '22 | $36M | -$36M | 0.0% | -85.3% | -$28M | — | $71M |
| Jun '22 | $40M | -$49M | 0.0% | -108.1% | -$35M | — | $82M |
| Mar '22 | $48M | -$41M | 0.0% | -72.6% | -$59M | — | $153M |
| Dec '21 | $126M | $39M | 0.0% | 37.2% | $25M | $169M | $190M |
| Sep '21 | $38M | -$52M | 0.0% | -116.2% | -$24M | — | $137M |
| Jun '21 | $23M | -$54M | 0.0% | -217.0% | -$56M | — | $141M |
How the market has priced KPTI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Karyopharm Therapeutics Inc.'s revenue has grown 6.2% per year. These are computed facts, not advice.
As of FY2025, Karyopharm Therapeutics Inc. reported — of total debt against $61M of cash; operating income covered interest expense -2.0×.
In FY2025, gross margin was —, operating margin -62.1%, and net margin -134.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.